Patents by Inventor Mats Eskil Elmér

Mats Eskil Elmér has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230033294
    Abstract: The present invention provides a novel isolated succinate prodrug as the free compound or a salt, hydrate, solvate or complex thereof being cell permeable and aimed for increasing the ATP-production in mitochondria. The compound is useful in the medical treatment of a range of diseases, in nutritional supplements, nutricosmetics and in cosmetics.
    Type: Application
    Filed: September 14, 2022
    Publication date: February 2, 2023
    Inventors: Magnus Joakim HANSSON, Alvar GRÖNBERG, Mats Eskil ELMÉR, Mark Richard FARMERY, Lee Robert WEBSTER, Steven James MOSS, Matthew Alan GREGORY
  • Patent number: 11565998
    Abstract: The present invention provides a novel isolated succinate prodrug as the free com-pound or a salt, hydrate, solvate or complex thereof being cell permeable and aimed for increasing the ATP-production in mitochondria. The compound is useful in the medical treatment of a range of diseases, in nutritional supplements, nutricosmetics and in cosmetics.
    Type: Grant
    Filed: June 18, 2020
    Date of Patent: January 31, 2023
    Assignee: ABLIVA AB
    Inventors: Magnus Joakim Hansson, Alvar Grönberg, Mats Eskil Elmér, Mark Richard Farmery, Steven James Moss, Lee Robert Webster, Matthew Alan Gregory
  • Publication number: 20220162162
    Abstract: The present invention provides a novel isolated succinate prodrug as the free com-pound or a salt, hydrate, solvate or complex thereof being cell permeable and aimed for increasing the ATP-production in mitochondria. The compound is useful in the medical treatment of a range of diseases, in nutritional supplements, nutricosmetics and in cosmetics.
    Type: Application
    Filed: June 18, 2020
    Publication date: May 26, 2022
    Inventors: Magnus Joakim HANSSON, Alvar GRÖNBERG, Mats Eskil ELMÉR, Mark Richard FARMERY, Steven James MOSS, Lee Robert WEBSTER, Matthew Alan GREGORY
  • Patent number: 9670175
    Abstract: Disclosed herein are mono or di-succinate compounds where one or both of the acid groups in the succinate core are protected in the form of biologically labile moieties, and the use of said compounds to enhance mitochondrial function. The compounds may be of formula (I) wherein R1 is H or an optionally substituted alkyl group or a group of formula (II) and R2 is independently a group according to formula (II) where formula (II) is as defined 10 herein.
    Type: Grant
    Filed: October 4, 2013
    Date of Patent: June 6, 2017
    Assignee: NEUROVIVE PHARMACEUTICALS AB
    Inventors: Hans Georg Fliri, Rhonan Lee Ford, David Arthur Scowen, Derek Gregory Batcheller, Kari Henrik Johannes Ehinger, Mats Eskil Elmer, Magnus Joakim Hansson, Karl Fredrik Lennart Sjovall
  • Publication number: 20150259317
    Abstract: Disclosed herein are mono or di-succinate compounds where one or both of the acid groups in the succinate core are protected in the form of biologically labile moieties, and the use of said compounds to enhance mitochondrial function. The compounds may be of formula (I) wherein R1 is H or an optionally substituted alkyl group or a group of formula (II) and R2 is independently a group according to formula (II) where formula (II) is as defined 10 herein.
    Type: Application
    Filed: October 4, 2013
    Publication date: September 17, 2015
    Applicant: Mitopharm Ltd
    Inventors: Hans Georg Fliri, Rhonan Lee Ford, David Arthur Scowen, Derek Gregory Batcheller, Karl Henrik Johannes Ehinger, Mats Eskil Elmér, Magnus Joakim Hansson, Karl Fredrik Lennart Sjövall